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Accurate DNA replication is essential to preserve
genomic integrity and prevent chromosomal insta-
bility-associated diseases including cancer. Key to
this process is the cells’ ability to stabilize and restart
stalled replication forks. Here, we show that the
EXD2 nuclease is essential to this process. EXD2
recruitment to stressed forks suppresses their
degradation by restraining excessive fork regres-
sion. Accordingly, EXD2 deficiency leads to fork
collapse, hypersensitivity to replication inhibitors,
and genomic instability. Impeding fork regression
by inactivation of SMARCAL1 or removal of RECQ1’s
inhibition in EXD2/ cells restores efficient fork
restart and genome stability. Moreover, purified
EXD2 efficiently processes substrates mimicking re-
gressed forks. Thus, this work identifies a mecha-
nism underpinned by EXD2’s nuclease activity, by
which cells balance fork regression with fork restora-
tion to maintain genome stability. Interestingly, from
a clinical perspective, we discover that EXD2’s
depletion is synthetic lethal with mutations in
BRCA1/2, implying a non-redundant role in replica-
tion fork protection.
INTRODUCTION
Faithful duplication of the genome during cell division ensures
accurate transmission of genetic information to daughter cells.
This process relies on the replication of the entire genomic
DNA during S-phase by thousands of replication forks. However,
replication fork stability is constantly challenged by damage toMolecular Cell 75, 605–619, A
This is an open access article undthe DNA template or progression through chromosomal regions
that are inherently difficult to replicate (Bhowmick and Hickson,
2017; Gaillard et al., 2015; Kolinjivadi et al., 2017a). These block-
ades can collapse replication forks, contributing to tumor pro-
gression by driving chromosomal instability (Burrell et al., 2013;
Hills and Diffley, 2014; Jeggo et al., 2016; Kass et al., 2016;
Zeman and Cimprich, 2014). To counteract this threat, cells
possess mechanisms to protect stalled replication forks, the
most important of which is the replication fork protection
pathway. This surveillance pathway, underpinned by the ATR ki-
nase, ensures inhibition of cell-cycle progression, suppression of
late origin firing, and restart of stalled replication forks (Jackson
and Bartek, 2009; Kass et al., 2016; O’Driscoll, 2012). Together,
these events ensure the faithful completion of DNA synthesis
(Cimprich and Cortez, 2008; Neelsen and Lopes, 2015; Zeman
and Cimprich, 2014). The importance of these responses is
highlighted by several cancer-predisposing human diseases
caused by mutations in various proteins contributing to replica-
tion fork stability (e.g., Seckel, Bloom, Werner, or Fanconi ane-
mia syndromes).
Recently, fork reversal has emerged as a key mechanism pro-
tecting stressed replication forks (Neelsen and Lopes, 2015; Ray
Chaudhuri et al., 2012; Zellweger et al., 2015). This process in-
volves regression of the fork, mediated by several SNF2-family
fork remodelers, and the formation of a 4-way junction. Once
the blockade is removed, regressed forks remain capable of
resuming DNA synthesis. The restart process is mediated by
the RECQ1 helicase, which has the ability to migrate and resolve
these 4-way structures (Berti et al., 2013; Neelsen and Lopes,
2015). Interestingly, in bacteria and yeast, a controlled nucleo-
lytic processing of regressed nascent strands stabilizes stalled
forks and prevents their reversal (Hu et al., 2012; Yeeles et al.,
2013). Whether a similar mechanism exists in mammalian cells
is currently unclear. Nevertheless, the ability to ‘‘resolve’’ re-
gressed replication forks is crucial for genome stability, because
the unregulated activity of fork remodelers induces degradationugust 8, 2019 ª 2019 The Authors. Published by Elsevier Inc. 605
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of nascent DNA and drives chromosomal instability (Couch et al.,
2013; Dungrawala et al., 2017; Thangavel et al., 2015).
Elegant work from several laboratories indicated that the
BRCA1/2 proteins protect nascent DNA at reversed forks (Kolin-
jivadi et al., 2017b; Lemac¸on et al., 2017; Mijic et al., 2017;
Schlacher et al., 2011; Taglialatela et al., 2017). The fork protec-
tion function of BRCA1/2 is RAD51-dependent, as cells depleted
for RAD51 or lacking the RAD51 stabilizing factor BOD1L,
display extensive nascent DNA degradation (Hashimoto et al.,
2010; Higgs et al., 2015; Schlacher et al., 2011). Fork protection
also requires components of the Fanconi anemia pathway,
which cooperate with BRCA1/2 in suppressing nascent DNA
degradation (Schlacher et al., 2011). More recently, several nu-
cleases (i.e., MRE11, DNA2, EXO1, and WRN) have also been
implicated in supporting damaged forks (Iannascoli et al.,
2015; Karanja et al., 2014; Lemac¸on et al., 2017; Thangavel
et al., 2015). Consequently, defective fork processing by these
enzymes leads to fork collapse, increased genomic instability,
and contributes to the development of chemotherapy resistance
(Chaudhuri et al., 2016; Neelsen and Lopes, 2015).
Despite extensive research, it is not fully understood how cells
maintain genome stability at sites of stalled DNA replication and
how the different nucleases and fork remodelers function to bal-
ance fork regression with fork restart to restore the replication
program. Because replication stress drives tumorigenesis and
restoration of fork protection in cancer cells facilitates the devel-
opment of chemotherapy resistance, it is crucial to understand
these mechanisms (Berti and Vindigni, 2016; Kolinjivadi et al.,
2017a; Yeeles et al., 2013).
Here, we show that the EXD2 nuclease, a protein recently
shown to promote genome stability in Drosophila (Cox et al.,
2007) and human cell lines (Biehs et al., 2017; Broderick et al.,
2016; Smogorzewska et al., 2010), is a component of the replica-
tion fork protection pathway. Accordingly, EXD2 is recruited to
stalled replication forks and cells lacking EXD2 or expressing a
nuclease-dead version of the protein display high levels of repli-
cation-associated genome instability. Mechanistically, we show
that EXD2 acts to counteract fork reversal and this activity is crit-
ical for suppression of uncontrolled degradation of nascent DNA
and efficient fork restart. In line with this, EXD2/ cells accumu-
late regressed replication forks and restricting fork regression by
silencing SMARCAL1 or removal of PARP1-dependent inhibition
of RECQ1 suppresses their degradation and allows for efficient
fork restart in these cells. Purified EXD2 can process synthetic
fork-like structures in vitro, and in vivo its nuclease activity
acts to suppress the collapse of terminally regressed forks. Un-
expectedly, we also discover that depletion of EXD2 confers aFigure 1. EXD2 Is Recruited to Stressed Replication Forks
(A) Western blot of iPOND samples. Thymidine chase analysis illustrates that EX
(B) Schematic of the proximity ligation assay (PLA) employed to detect colocaliz
(C) Percentage of cells with MRE11/biotin PLA foci (mean ± SEM, n = 3 independe
as a nuclear counterstain. Scale bar, 10 mm.
(D) Percentage of cells withGFP/biotin PLA foci (mean ± SEM, n = 3 independent e
Right: representative images of PLA foci (red), DAPI acts as a nuclear countersta
(E) Laser microirradiation induces rapid redistribution of GFP-EXD2 to damaged
generated DNA lesions. GFP-CtIP was used as a positive control. Scale bar, 10
(F) Quantification of GFP-EXD2 (left panel) and GFP-CtIP (right panel) recruitme
nR 10 cells from 2 independent experiments).synthetic lethal interaction with BRCA1/2, suggesting a non-
redundant function between these repair factors. Taken
together, our findings uncover a previously unknown role for
EXD2 in the replication stress response and also identifies
EXD2 as a potential druggable target for cancer therapy.
RESULTS
EXD2 Is Recruited to Replication Forks following
Replication Stress
Recently, we have employed isolation of proteins on nascent
DNA (iPOND) coupled with mass spectrometry to identify factors
recruited to stalled replication forks (Higgs et al., 2015). This
analysis identified EXD2, as a factor recruited to replication forks
(Figure S1A). We confirmed these results by western blotting
(Figure S1B) (Coquel et al., 2018). To test if EXD2 associates spe-
cifically with replication forks, we performed an iPOND analysis
coupled with a thymidine-chase. This revealed that the abun-
dance of EXD2 decreased upon the chase with thymidine (Fig-
ure 1A) as observed previously for PCNA (Sirbu et al., 2011).
To further verify EXD2’s association with newly replicated
DNA, we combined EdU labeling with the proximity-ligation
assay (PLA) to gauge the proximity of proteins with labeled
nascent DNA (Higgs et al., 2015; Taglialatela et al., 2017) (Figures
1B and S1C). To this end, U2OS cells stably expressing GFP-
EXD2 (Figure S1D) were labeled with EdU and subsequently
treated with hydroxyurea (HU) followed by PLA to detect protein
association with biotin-labeled nascent DNA. First, we validated
this approach by testing the co-localization of MRE11 with
nascent DNA after replication stress. As expected, MRE11 was
significantly enriched following HU treatment (Figure 1C),
consistent with its role at the stressed forks (Costanzo, 2011; Ha-
shimoto et al., 2010; Taglialatela et al., 2017). Importantly, we
could also readily detect nuclear PLA signal for EXD2 in cells
treated with HU (Figure 1D), which was significantly enriched
compared to untreated and control samples. To ascertain that
this phenotype is not restricted to the GFP tag or its position,
we repeated these experiments using U2OS cells expressing
FLAG-tagged EXD2 (Broderick et al., 2016) and C-terminally
GFP-tagged EXD2 (Figures S1E and S1F), confirming the spec-
ificity of its nuclear co-localization with stalled forks. Moreover,
time-dependent analysis of EXD2 recruitment to stalled forks re-
vealed similar kinetics to those of MRE11 (Figures S2A–S2D).
Next, to gain further insight into the dynamics of EXD2 recruit-
ment to DNA lesions, we employed laser micro-irradiation com-
bined with live cell imaging (Suhasini et al., 2013). This analysis
revealed that GFP-EXD2 is rapidly recruited to laser-generatedD2 specifically associates with the replisome. PCNA acts as a control.
ation of target proteins with nascent DNA.
nt experiments, t test). Right: representative images of PLA foci (red), DAPI acts
xperiments, t test) in U2OS control cells and U2OS cells expressing GFP-EXD2.
in. Scale bar, 10 mm.
chromatin; representative images showing GFP-EXD2 accumulation at laser-
mm.
nt kinetics (intensity versus time) to laser-generated DNA lesions (mean ± SE,
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DNA damage, with faster kinetics than those of GFP-CtIP (Fig-
ures 1E and 1F; ,Video S1), underscoring its early role in the
DNA repair processes. Taken together, this data suggest that
EXD2 is rapidly recruited to damaged chromatin and associates
with sites of DNA replication.
EXD2 Promotes Global Replication Fork Dynamics in
Response to Replicative Stress
To shed light on the role of EXD2 during DNA replication, we
analyzed the survival of EXD2/ cells exposed to agents that
impede fork progression. Loss of EXD2 sensitizes cells not
only to MMC, CPT, and MMS as reported (Broderick et al.,
2016; Smogorzewska et al., 2010) but also other drugs capable
of blocking fork progression, i.e., cisplatin, gemcitabine, and HU
(Figures 2A, S2E, and S2F), suggesting a general role in miti-
gating replicative stress.
To address the mechanism by which EXD2 promotes DNA
replication, we used the DNA fiber assay to visualize individual
replication forks. First, we quantified replication fork asymmetry
in unchallenged cells (Schwab et al., 2015). We observed a sig-
nificant increase in sister fork asymmetry in HeLa EXD2/ cells
(Figure 2B), suggesting increased rates of fork stalling or
collapse. Consistently, transient exposure of EXD2-deficient
cells to HU impeded replication fork dynamics (Figure 2C) as
well as restart of stressed forks (Figure 2D). Moreover, forks
that were able to recover DNA synthesis did so with a significant
delay (Figure 2D). To determine the fate of stalled replication
forks, we analyzed the formation of 53BP1 foci, a marker of dou-
ble strand break (DSB) induction. This analysis revealed that loss
of EXD2 leads to a significant increase in the number of 53BP1
foci per S/G2-cell, likely due to a wide-spread fork collapse re-
sulting in the formation of DSBs (Figure 3A). Consistent with
this, EXD2/ cells displayed high levels of chromatid-type aber-
rations associated with collapsed replication forks (Figures 3B
and 3C). Finally, because EXD2 is a 30-50 exonuclease (Broderick
et al., 2016), we tested the ability of HeLa EXD2/ cells comple-
mented with either wild type (WT) or nuclease-dead EXD2 to
restore the normal replication program (i.e., fork symmetry).
Only cells expressing WT EXD2, but not the nuclease-dead
mutant, are capable of restoring efficient fork progression (Fig-
ures 3D and S2G). Consistent with this, purified EXD2 can pro-
cess synthetic fork-like structures in vitro (Figure S2H) suggest-
ing that its nuclease activity facilitates fork repair. Collectively,
these data indicate that EXD2 is a component of the replication
fork protection pathway supporting efficient DNA synthesis and
suppressing genome instability.
Loss of EXD2 Leads toMitotic Abnormalities Associated
with Under-Replicated DNA
Failure to fully complete DNA replication leads to cells entering
mitosis with under-replicated DNA, causing chromosome
breakage and inhibiting cells’ ability to segregate chromosomes
(Burrell et al., 2013). This can be visualized as formation of
anaphase bridges, 53BP1 OPT domains in daughter cells, and
formation of micronuclei (MN) (Harrigan et al., 2011; Lukas
et al., 2011). In support of EXD2’s role in promoting genome
duplication, EXD2-deficiency correlates with high levels of
anaphase bridges or 53BP1 OPT domains (Figures 4A and 4B).608 Molecular Cell 75, 605–619, August 8, 2019Additionally, the frequency of MN is also elevated by 2-fold in
EXD2/ cells as compared to WT (Figure 4C). Importantly,
only the WT protein, but not the nuclease-dead mutant, is
capable of complementing these defects (Figures 4D–4F).
Collectively, these data indicate that EXD2 promotes recovery
of stressed forks thereby suppressing fork collapse and the gen-
eration of replication intermediates that may interfere with chro-
mosomal segregation and drive genome instability.
EXD2 Protects Replication Forks against Uncontrolled
Degradation
Recent work suggests that stressed replication forks undergo
excessive nucleolytic degradation (Chaudhuri et al., 2016; Ha-
shimoto et al., 2010; Karanja et al., 2014; Lachaud et al., 2016;
Schlacher et al., 2011). This process drives genome instability
and underpins the ability of cancer cells to become chemoresist-
ant. Key players in this process are the BRCA1/2 proteins that
inhibit MRE11 nuclease-dependent fork resection by regulating
RAD51 loading onto stalled forks (Chaudhuri et al., 2016; Kolin-
jivadi et al., 2017b; Lemac¸on et al., 2017; Mijic et al., 2017; Pa-
sero and Vindigni, 2017). To determine the mechanism by which
EXD2 protects stressed forks, we tested if EXD2 loss impacts on
fork resection by employing a modified DNA fiber protocol as
described recently (Chaudhuri et al., 2016). Briefly, WT and
EXD2-deficient HeLa cells were incubated with IdU and CldU
and then exposed to HU. Strikingly, EXD2-deficient cells also
displayed significantly elevated fork resection compared to WT
cells, reflecting degradation of newly replicated DNA after fork
arrest (Figure 5A, left panel). Importantly, this seems to be a gen-
eral, non-cell line restricted phenotype, as we observed a similar
response in U2OS EXD2/ cells (Figure 5A, right panel). In line
with EXD2’s role in protecting stalled forks, we also observed
increased co-localization between EXD2 and the fork-protection
factor BRCA1 upon replicative stress (Figure 5B).
Pathological degradation of unstable forks has been attributed
to the deleterious activity of MRE11 (Chaudhuri et al., 2016; Ko-
linjivadi et al., 2017b; Mijic et al., 2017; Schlacher et al., 2011).
Because EXD2 functionally interacts with MRE11 during homol-
ogy-mediated repair (Broderick et al., 2016), we asked if MRE11
can drive fork processing upon loss of EXD2. To test this, we em-
ployed mirin, an MRE11 inhibitor shown to block fork resection
(Schlacher et al., 2011; Taglialatela et al., 2017). Strikingly, treat-
ment with mirin reversed the excess fork degradation seen in
EXD2/ cells (Figure 5C). A similar result was achieved using
small interfering RNA (siRNA) against MRE11 (Figures 5D and
S3A). Because BRCA1/2 have been shown to prevent MRE11-
dependent degradation of stressed forks by promoting RAD51
loading (Hashimoto et al., 2010; Schlacher et al., 2011), we
considered the possibility that loss of EXD2 impairs recruitment
or retention of RAD51 at nascent DNA. However, this does not
seem to be the case, as we do not see any major change in
the number of RAD51-dependent PLA foci at the sites of fork
stalling in EXD2/ cells in contrast to BRCA1 knockdown (Fig-
ure S3B). Consistently, the level of BRCA1 loading at the vicinity
of stalled forks is also similar between WT and EXD2/ cells
(Figure S3C). Finally, and in contrast to BRCA1 deficiency
(Taglialatela et al., 2017), we also did not observe an
increased recruitment of MRE11 to stalled forks in EXD2/ cells
CB
A
D
Figure 2. EXD2 Promotes Global Replication Fork
Dynamics in Response to Replicative Stress
(A) Survival of HeLa control and HeLa EXD2/ cells
treated with the indicated doses of cisplatin, gemcitabine,
mitomycin C, or hydroxyurea (mean ± SEM, n = 3 inde-
pendent experiments).
(B) Boxplot of CldU tract length ratios of associated sister
forks from HeLa WT and EXD2/ cells. (5–95 percentile,
n R 60 sister fork pairs pooled from 3 independent ex-
periments, Mann-Whitney).
(C) Boxplot of CldU/IdU tract ratios of HeLa WT and
EXD2/ cells treated with 1 mM HU (5–95 percentile,
n R 300 tracts pooled from 3 independent experiments,
Mann-Whitney).
(D) Boxplot of CldU/IdU tract ratios of HeLa WT and
EXD2/ cells (left panel) and quantification of the per-
centage of stalled forks (red only tracts) in HeLa WT and
EXD2/ cells (right panel) (5–95 percentile, nR 300 tracts
pooled from 3 independent experiments Mann-Whitney
[left panel]; n = 3 independent experiments, t test
[right panel]).
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(Figure S3D, note the increased level of MRE11 signal in cells
depleted for BRCA1) (Taglialatela et al., 2017). Taken together,
this data suggests a previously undescribed RAD51- and
BRCA1/2-independent mechanism of fork protection under-
pinned by EXD2’s activity.
Perturbation to replication fork progression in mammalian
cells induces a high frequency of fork reversal (Zellweger et al.,
2015). This process is controlled by the action of multiple fork
remodelers, which promote efficient fork repair and restart. Un-
scheduled fork reversal, however, is toxic and results in patho-
logical degradation of nascent DNA driving genome instability
(Kolinjivadi et al., 2017b; Mijic et al., 2017; Neelsen and Lopes,
2015). We therefore wondered if fork degradation observed in
EXD2/ cells could be due to its role in counteracting regression
of stalled forks. We tested this hypothesis in several ways; first,
we examined the impact of depleting the SMARCAL1 fork re-
modeler on fork degradation in cells lacking EXD2. Strikingly,
SMARCAL1 knockdown suppressed resection of stressed forks
in these cells (Figures 6A, 6B, and S3E). Second, fork reversal is
counteracted by the action of the RECQ1 helicase, which is in-
hibited by PARP1 (Berti et al., 2013). We reasoned therefore,
that inhibiting PARP1 should de-repress RECQ1 and increase
its fork restoration activity (Berti et al., 2013; Margalef et al.,
2018). In support of our hypothesis, treatment of EXD2-deficient
cells with the PARP1 inhibitor olaparib abolished the resection
phenotype of EXD2/ cells (Figures 6A and 6C). Unscheduled
fork reversal coupled with fork degradation is a pathological pro-
cess that inhibits replication fork restart. Therefore, if EXD2 acts
to limit fork regression, limiting reversal in EXD2/ cells should
improve the recovery of stalled forks. In support of this hypothe-
sis, this is exactly what we observe. Downregulating SMARCAL1
or removing the PARP1-dependent inhibition of RECQ1 restores
the ability of EXD2/ cells to resume DNA synthesis, and impor-
tantly, ameliorates the genome instability of these cells (Figures
6D, 6E, and S4A–S4C). Contrary to this, silencing of RECQ1 is
epistatic with EXD2 deficiency suggesting that these two pro-
teins function within the same mechanism to counteract fork
regression (Figures S5A–S5D, and S5G [model]). However,
because PARP1 plays multiple roles in protecting stalled forks,
including the recruitment of MRE11 to promote HR-dependent
fork restart (Bryant et al., 2009), we considered the possibility
that inhibiting fork resection alone may be enough to rescue
fork restart in EXD2/ cells. Importantly, this is not the case
as treatment with mirin, which inhibits over-resection in EXD2/
cells, does not rescue the defective fork restart (Figure S5E). To
further support this hypothesis, we analyzed PARP1 recruitment
to nascent DNA using the PLA assay. We reasoned that because
PARP1-catalyzed PARylation of RECQ1 at stalled replication
forks regulates its activity (Berti et al., 2013), PARP1 accumula-Figure 3. EXD2’s Nuclease Activity Is Required to Suppress Replicatio
(A) Quantification of the frequency of 53BP1 foci in HeLaWT and EXD2/ S/G2 c
DAPI acts as a nuclear stain (mean ± SEM, n = 3 independent experiments, Man
(B) Quantification of the frequency of chromosomal aberrations frommitotic sprea
pooled from 3 independent experiments, t test).
(C) Representative images of metaphase spreads from B). Arrows indicate chrom
(D) Boxplot of CldU tract length ratios of associated sister forks from HeLa WT, E
EXD2 nuclease dead (ND) mutant protein (5–95 percentile, nR 60 sister fork pation on nascent DNA could serve as an indirect readout of fork
regression (Margalef et al., 2018). In support of our hypothesis,
we see a significant increase in the PLA signal for PARP1-EdU
in cells lacking EXD2 as compared to control. Crucially, this is
rescued by the knockdown of SMARCAL1 confirming that the
PLA signal is derived from regressed forks (Figures 6F and S5F).
Reversed replication forks are predicted to arise via the
translocation of the branch point of a stalled fork, followed by an-
nealing of the two newly synthesized strands to create a 4-way
junction. We hypothesized that EXD2-dependent nucleolytic
processing of the regressed nascent strand(s) could counteract
fork reversal. We therefore analyzed the ability of purified EXD2
to process structures mimicking reversed replication forks,
including those with extruded nascent strands. Consistent with
our hypothesis, EXD2was able to degrade these substrates (Fig-
ures 6G and S6A–S6C). Collectively, these results support the
conclusion that EXD2 nuclease-dependent fork processing
counteracts fork regression and promotes restoration of active
replication forks.
EXD2 Depletion Is Synthetic Lethal with BRCA1/2
Our analysis thus far suggested that EXD2 suppresses replica-
tive stress via a mechanism that is distinct from the role of the
BRCA1/2 genes in this process. We therefore considered the
possibility that EXD2 is required to avert replication catastrophe
in cells lacking BRCA1/2. With this in mind, we first analyzed the
proliferative capabilities of both single and double mutants.
Strikingly, combined depletion of EXD2 with BRCA1/2 in HeLa
or U2OS cells leads to an almost complete inhibition of cell
growth (Figures 7A–7C and S6D–S6F). Importantly, this pheno-
type could be recapitulated in BRCA1/2-deficient cancer cell
lines (Dre´an et al., 2017) (Figures 7D, 7E, S6G, and S6H) and is
dependent on the nuclease activity of EXD2 (Figures 7F and
S6I). To further our understanding of this synergistic interaction,
we analyzed the frequency of micronuclei formation, as a
readout of chromosomal instability. Consistent with the growth
inhibition data, we noticed a marked increase in micronuclei
formation in the double deficient mutants as compared to the
singles (Figure 7G).
Surprisingly, we were unable to detect a significant increase in
fork stalling or degradation in these double mutants (Figures S7A
and S7B). Intriguingly, however, we noticed a dramatic defi-
ciency of EXD2/ cells to generate chromosome end-to-end
fusions (Figure S7C), which are dependent on the alternative
end-joining pathway (Alt-EJ) (Mateos-Gomez et al., 2015). This
pathway relies on limited resection of DSBs by the MRE11
nuclease to generate short stretches of homology used to bridge
the break (Howard et al., 2015), and recent work has implicated
Alt-EJ in survival of BRCA1/2-deficient tumors (Ceccaldi et al.,n Fork Collapse
ells and representative images. Cyclin A (green) acts as a marker for S/G2 cells,
n-Whitney). Scale bar, 10 mm.
ds from HeLa WT and EXD2/ cells (mean ± SEM, n = 75 metaphase spreads
atid breaks. Scale bar, 6.5 mm.
XD2/, and EXD2/ cells complemented with either Flag-EXD2 WT or Flag-
irs pooled from 3 independent experiments, Mann-Whitney).
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Figure 4. Loss of EXD2 Leads to Mitotic Abnormalities Associated with Under-Replicated DNA
(A) Quantification of the HeLa WT and EXD2/ anaphase or telophase cells showing DAPI-positive bridges (mean ± SEM, n = 3 independent experiments, chi-
square). Scale bar, 10 mm.
(B) Quantification of HeLa WT and EXD2/ G1 cells with 53BP1 OPT domains in G1 cells (left panel). Quantification of the number of 53BP1 OPT domains per
positive cell in HeLa WT and EXD2/ cells (right panel) and representative images (mean ± SEM, n = 3 independent experiments, chi-square). Scale bar, 20 mm.
(C) Quantification of HeLa WT and EXD2/ cells showing MN and representative images. Phalloidin acts as a cytosolic marker (mean ± SEM, n = 3 independent
experiments, chi-square). Scale bar, 20 mm.
(D) Quantification of HeLa WT, EXD2/, and EXD2/ cells complemented with either Flag-EXD2 WT or Flag-EXD2 nuclease dead (ND) mutant protein for
anaphase or telophase cells showing DAPI-positive bridges (mean ± SEM, n = 3 independent experiments, chi-square).
(E) Quantification of HeLa WT, EXD2/, and EXD2/ cells complemented with either Flag-EXD2 WT or Flag-EXD2 nuclease dead (ND) mutant protein for G1
cells with 53BP1 OPT domains (mean ± SEM, n = 3 independent experiments, chi-square).
(F) Quantification of HeLa WT, EXD2/, and EXD2/ cells complemented with either Flag-EXD2 WT or Flag-EXD2 nuclease dead (ND) mutant protein for cells
showing MN (mean ± SEM, n = 3 independent experiments, chi-square).
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Figure 5. EXD2 Protects Replication Forks
against Uncontrolled Degradation of
Nascent DNA
(A) Boxplot of CldU/IdU tract ratios of HeLa WT
and EXD2/ cells (left panel) and U2OS WT
and EXD2/ cells (right panel) (5–95 percentile,
nR 300 tracts pooled from 3 independent exper-
iments, Mann-Whitney).
(B) Quantification of U2OS cells or U2OS cells
stably expressing GFP-EXD2 for GFP/BRCA1 PLA
foci (mean ± SEM from 3 independent experi-
ments, Mann-Whitney) and representative images.
Scale bar, 10 mm.
(C) Boxplot of CldU/IdU tract ratios of HeLa WT
and EXD2/ cells untreated or pre-treated
with MRE11 inhibitor Mirin (50 mM) (5–95 percen-
tile, n R 300 tracts pooled from 3 independent
experiments, Mann-Whitney).
(D) Boxplot of CldU/IdU tract ratios of HeLa
WT and EXD2/ cells upon MRE11 knock-down
(5–95 percentile, n R 300 tracts pooled from 3
independent experiments, Mann-Whitney).2015; Mateos-Gomez et al., 2015). Because EXD2 functionally
interacts with the MRE11 nuclease (Broderick et al., 2016), we
considered the possibility that the synthetic growth defect may
reflect a lack of fork protection coupled with the loss of Alt-EJ
to rescue unprotected forks. To test this, we depleted EXD2 in
a U2OS cell line expressing the Alt-EJ reporter construct (Gunn
et al., 2011), using BRCA2 and MRE11 knockdown as a positive
and negative control, respectively. As previously reported,Molesilencing of BRCA2 increased the level
of Alt-EJ events whereas knockdown of
MRE11 reduced its efficiency (Ceccaldi
et al., 2015; Howard et al., 2015). Strik-
ingly, we noticed that Alt-EJ was also
significantly impaired in the absence of
EXD2 (Figures 7H, S7D, and S7E). Collec-
tively, these data suggest a role for EXD2
in promoting repair of chromosomal
breaks in the absence of BRCA1/2 by an
alternative end-joining pathway. Because
Alt-EJ is essential for survival of BRCA1/2
mutants (Ceccaldi et al., 2015; Mateos-
Gomez et al., 2015), we propose that
combined depletion of BRCA1/2 and
EXD2 results in an accumulation of
broken replication forks, which cannot
be rescued by the Alt-EJ backup mecha-
nism driving mitotic catastrophe and
cell death, even under normal growth
conditions.
DISCUSSION
While addressing the key question of
how cells maintain genome stability at
stressed replication forks, we have deter-
mined that EXD2 is essential for an effi-cient response to replicative stress. We reveal that EXD2 is
recruited to stalled forks with fast kinetics, similar to those
observed for the MRE11 nuclease (Haince et al., 2008; Suhasini
et al., 2013), and its loss compromises efficient replication fork
progression. In line with this, EXD2/ cells display sensitivity
to a range of agents that interfere with DNA replication, including
clinically relevant anti-cancer drugs. In keeping with EXD2’s role
in mitigating replicative stress, EXD2 mutant cells enter mitosiscular Cell 75, 605–619, August 8, 2019 613
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with under-replicated DNA, which leads to elevated levels of
anaphase bridges, G1-associated 53BP1 OPT domains, and
micronuclei, likely all of which contribute to the increased chro-
mosome breakage observed in these cells. Given the significant
increase in 53BP1 foci (a marker of DSBs) in EXD2/ cells dur-
ing S-phase, we postulate that loss of EXD2 results in replication
fork collapse.
Fork reversal has recently emerged as an important mecha-
nism of cellular responses to replicative stress (Neelsen and
Lopes, 2015). Uncontrolled fork reversal, however, can result in
fork degradation, irreversible collapse, and genome instability
(Kolinjivadi et al., 2017a; Pasero and Vindigni, 2017; Yeeles
et al., 2013). Surprisingly, we discovered that EXD2 acts at
stressed forks to suppress their uncontrolled regression, most
likely by enzymatically processing stalled forks to restrict their
conversion to reversed forks. Our conclusion is supported by
the following observation; inhibition of fork regression by down-
regulation of SMARCAL1 or de-repressing PARP1-dependent
inhibition of RECQ1 fork restoration activity rescues not only
the excessive resection of stalled forks but also fork restart in
EXD2/ cells. Consistently, examining the association of
PARP1 with nascent DNA indicates a significant increase in
fork reversal in the absence of EXD2, which is corrected by
SMARCAL1 knockdown. Crucially, however, treatment with
mirin, which inhibits fork resection in EXD2/ cells, does not
rescue fork restart. One model to explain how EXD2 functions
in counteracting fork reversal is that large single-stranded DNA
(ssDNA) gaps formed behind the stalled fork (Kolinjivadi et al.,
2017b), and/or the already regressed nascent leading strand re-
veals a 30 DNA end that can be acted upon by EXD2. Subse-
quently, nucleolytic processing of such a substrate alone, or
together with the resection of the opposite nascent strand,
may promote re-annealing of the parental strands and fork back-
tracking (Pasero and Vindigni, 2017). A second model, which we
favor, is that at the initial stage of fork regression, the nascent
leading strand becomes dissociated (due to the spatial configu-
ration of the fork, dissociated nascent strandsmay not be able to
anneal with each other initially) or at the later stage, is actively
displaced by RECQ1’s helicase activity, and subsequently,
EXD2-dependent resection of the unpaired strandwould prevent
fork reversal (i.e., formation of a 4-way junction). In turn, this
would shift the balance toward restoration of an active fork.Figure 6. EXD2 Acts to Counteracts Replication Fork Regression
(A) Schematic of the process of replication fork reversal and RECQ1-mediated res
pathological degradation. Knockdown of SMARCAL1 suppresses fork reversal a
thus, PARP inhibition de-represses RECQ1 and increases its activity counteract
(B) Boxplot of CldU/IdU tract ratios of HeLa WT and EXD2/ cells upon SMARC
experiments, Mann-Whitney).
(C) Boxplot of CldU/IdU tract ratios of HeLa WT and EXD2/ cells untreated o
2 independent experiments, Mann-Whitney).
(D) Boxplot of CldU/IdU tract ratios of HeLa WT and EXD2/ cells upon SMARC
experiments, Mann-Whitney).
(E) Boxplot of CldU/IdU tract ratios of HeLa WT and EXD2/ cells untreated or t
dependent experiments, Mann-Whitney).
(F) Quantification of the average number of PLA foci per focus positive cell in HeL
(mean ± SEM, n = 4 independent experiments, Mann-Whitney). Scale bar, 10 mm
(G) Phosphor imaging of 50 radiolabeled indicated DNA substrates (labeled stran
amounts of time with EXD2 WT protein.Indeed, EXD2 and RECQ1 deficiencies are epistatic and purified
EXD2 is capable of degrading 30 ssDNA within a substrate
mimicking reversed forks with an extruded (unpaired) nascent
strand. This could be an important mechanism restricting unde-
sirable regression of a fork before the lagging strand is fully
mature and/or upon transient dissociation of the leading strand
during replisome staling. Because the two sister chromatids
are physically linked at the replication fork, displacement of the
leading nascent strand (i.e., due to a transient fork reversal) fol-
lowed by RAD51 filament formation could initiate homology
search, increasing ectopic HR-driven recombination, a consid-
erable problem for highly repetitive genomes (Lambert et al.,
2010; Mizuno et al., 2009, 2013). Of note, leading- and lagging-
strand polymerases are not always coordinated, and ssDNA in-
termediates form even at active forks (Graham et al., 2017).
Accordingly, processing of the dissociated nascent strands in
bacteria and yeast has been shown to enable replication fork
structures to be regenerated, limiting HR-dependent chromo-
somal rearrangements (Courcelle et al., 2003; Hu et al., 2012; Ira-
qui et al., 2012; Yeeles et al., 2013).
Interestingly, it has been proposed that efficient recovery of
stalled forks in mammalian cells may require the action of an
as yet unidentified 30-50 nuclease (Kolinjivadi et al., 2017a;
Pasero and Vindigni, 2017). Therefore, it is tempting to speculate
that EXD2, itself a 30-50nuclease, could be this missing
factor. Consistent with this, our analysis shows that EXD2’s
nuclease activity is essential for its role in promoting recovery
of stressed forks and suppression of replication-associated
genome instability.
EXD2 Is Synthetic Lethal with BRCA1/2
Germline mutations in the BRCA1/BRCA2 genes account for up
to 80% of familial breast and ovarian cancer cases (King et al.,
2003; Prakash et al., 2015). In their absence, nascent DNA at
the stalled fork is extensively degraded, likely contributing to
BRCA1/2-associated genome instability and sensitivity to repli-
cation stress-inducing therapies (Ceccaldi et al., 2015; Chaud-
huri et al., 2016). Our observation that loss of EXD2 induces
excessive fork degradation that is not coupled to impaired
RAD51 or BRCA1 association with stalled forks prompted us
to analyze the genetic interaction between BRCA1/2 and
EXD2. Surprisingly, we discovered that combined deficiency intart of regressed forks (upper panel); upon loss of EXD2 reversed forks undergo
nd promotes fork restart (bottom left panel); RECQ1 is inhibited by parylation
ing fork regression (bottom right panel).
AL1 knockdown (5–95 percentile, nR 200 tracts pooled from 3 independent
r treated with 10 mM olaparib (5–95 percentile, n R 200 tracts pooled from
AL1 knockdown (5–95 percentile, nR 180 tracts pooled from 3 independent
reated with 10 mM olaparib (5–95 percentile, nR 160 tracts pooled from 3 in-
a and EXD2/ cells upon SMARCAL1 knockdown and representative images
.
d shown in red, length of the regressed arm indicated) incubated for indicated
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these factors is incompatible with cell proliferation, even in the
absence of any exogenous challenge. Therefore, unlike deple-
tion of fork remodelers (Kolinjivadi et al., 2017b; Mijic et al.,
2017; Taglialatela et al., 2017), loss of EXD2 aggravates genomic
instability associated with BRCA1/2 deficiencies. Tumors defi-
cient in one DNA repair pathway often rely on a compensatory
mechanism to resolve the damage. Consistent with this notion,
we show a role for EXD2 in promoting repair of DSBs via alterna-
tive end-joining (Alt-EJ). Thus, in the absence of both EXD2 and
BRCA1/2 proteins, unprotected replication forks collapse and
cannot be rescued by either canonical HR or the Alt-EJ backup
mechanism, ultimately compromising cell viability.
In conclusion, we show that EXD2 promotes efficient genome
duplication by counteracting regression of stalled forks (Figures
7I and S5G). Since replicative stress is one of themajor drivers of
tumorigenesis and aging (Flach et al., 2014; Gaillard et al., 2015;
Halazonetis et al., 2008), this work provides an important insight
into mechanisms protecting cells against acquisition of DNA
damage. In addition, our results offer a potential therapeutic
target for tumors with BRCA1/2 deficiency. In the longer term,
it would be worthy to assess the penetrance of this phenotype
in other HR-deficient cancers.
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Antibodies
a-Tubulin Sigma T5168; RRID: AB_477579
BRCA1 Millipore OP-92; RRID: AB_2750876
BRCA2 Millipore OP-95; RRID: AB_2067762
EXD2 Sigma-Aldrich HPA005848; RRID: AB_1078768
MCM2 Abcam ab4461; RRID: AB_304470
MRE11 Abcam ab214; RRID: AB_302859
PCNA Santa-Cruz PC-10; RRID: AB_628110
RECQ1 Santa-Cruz SC-166388; RRID: AB_2178425
SMARCAL1 Santa-Cruz Sc-376377; RRID: AB_10987841
53BP1 Millipore MAB3802; RRID: AB_2206767
Cyclin A Santa-Cruz sc751; RRID: AB_631329
Biotin Bethyl Laboratories, A150-109A; RRID: AB_67327
Biotin Jackson Immunoresearch 200-002-211; RRID: AB_2339006
BRCA1 Santa-Cruz sc6954; RRID: AB_626761
Donkey anti-Mouse IgG (H+L) Secondary
Antibody, Alexa Fluor 555
Thermo Fisher Scientific A31570; RRID: AB_2536180
Donkey Anti-Rabbit IgG (H+L) Antibody,
Alexa Fluor 488 Conjugated
Thermo Fisher Scientific A21206; RRID: AB_141708
Anti-BrdU antibody; Rat monoclonal [BU1/75 (ICR1)] Abcam ab6326; RRID: AB_305426
Purified Mouse Anti-BrdU Clone B44 BD Biosciences 347580; RRID: AB_400326
Sheep anti-mouse Cy3 antibody Sigma-Aldrich C2181; RRID: AB_258785
Goat anti-Rat IgG (H+L) Cross-Adsorbed
Secondary Antibody, Alexa Fluor 488
Thermo Fisher Scientific A11006; RRID: AB_2534074
Chemicals, Peptides, and Recombinant Proteins
PreScission Protease GEHealthcare 27084301
Hydroxyurea Sigma-Aldrich H8627
Gemcitabine hydrochloride Sigma-Aldrich G6423-10MG
5-Iodo-20-deoxyuridine Sigma-Aldrich I7125
5-Chloro-20-deoxyuridine MP Biomedicals 105478
Mitomycine C Sigma-Aldrich M4287
Cis-diamineplatinum dichloride Sigma-Aldrich P4394
Mirin Sigma- Aldrich M9948
Olaparib AZD2281 Seleck Chem S1060
Lipofectamine 2000 Thermo Fisher Scientific 11668019
HiPerfect QIAGEN 301707
Vectashield Vector Lab H-1000
Vectashield with DAPI Vector Lab H-1200
Immobilon Western Chemiluminescent HRP substrate Millipore WBKLS0500
Critical Commercial Assays
Duolink In Situ Red Starter Kit Mouse/Rabbit Sigma-Aldrich DUO92101-1KT
Invitrogen Molecular Probes Click-iT EdU Imaging
Kit with Alexa Fluor 488, 594, and 647 Azides
Fischer Scientific 13435356
Biotin-dPEG7-azide Quanta Biodesign/ Stratech 10825-QUA
EdU (5-ethynyl-20-deoxyuridine) Thermo Fisher Scientific E10187
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REAGENT or RESOURCE SOURCE IDENTIFIER
Deposited Data
Raw image files This study, Mendeley https://doi.org/10.17632/gbc75sg6c7.1
Experimental Models: Cell Lines
HeLa From Fumiko Esashi Laboratory N/A
HeLa S3 From Ian D. Hickson Laboratory N/A
U2OS From Fumiko Esashi Laboratory N/A
RPE-1 From Andrew Blackford Laboratory N/A
HEK293FT From Grant Stewart Laboratory N/A
SUM149 From Chris Lord Laboratory Dre´an et al., 2017
SUM149 revertant From Chris Lord Laboratory Dre´an et al., 2017
DLD1 From Chris Lord Laboratory Dre´an et al., 2017
DLD1 BRCA2 / From Chris Lord Laboratory Dre´an et al., 2017
HeLa EXD2 / Wojciech Niedzwiedz Laboratory, Broderick et al., 2016
U2OS EXD2 / This study N/A
RPE1 EXD2 / This study N/A
RPE1 EXD2 ND/ND This study N/A
HeLa EXD2 / + Flag-HA-EXD2 WT This study N/A
HeLa EXD2 / + Flag-HA-EXD2 ND This study N/A
U2OS + GFP-EXD2 This study N/A
U2OS + EXD2-GFP This study N/A
Oligonucleotides
gRNA1; GTCTAATTCACTTCTAAGCAA This study N/A
gRNA2; GACTTGGAATTGACTGTGAGT This study N/A
ssODN_ND; AGGAGGCAGAGTGGGATCAAAT
CGAGCCCTTGCTTAGATCTGAATTAGAAGATT
TTCCAGTACTTGGTATCGCTTGTGCGTGGGTA
AGTTAAAAAGCAAAAGTTAAAAAA
This study N/A
siBRCA1- ACCAUACAGCUUCAUAAAUAA This study N/A
siBRCA2 ON-TARGETplus SMART pool, Dharmacon L-003462-00-0005
siEXD2 – CAGAGGACCAGGUAAUUUA Dharmacon Broderick et al., 2016
siEXD2-2 (ON-TARGETplus EXD2 siRNA) Dharmacon L-020899-02-0005
siEXD2 (30 UTR) GAACAAGGAGUCAAAUUUA Dharmacon Broderick et al., 2016
siSMARCAL1 ON-TARGETplus SMARTpool Dharmacon L-013058-00-0005)
siMRE11 GGAGGUACGUCGUUUCAGA Dharmacon Broderick et al., 2016
siRECQ1 ON-TARGETplus SMARTpool Dharmacon L-013597-00-0005
siLuciferase CGTACGCGGAATACTTCGA Dharmacon Broderick et al., 2016
ON-TARGETplus Non-targeting Pool Dharmacon D-00180-10-20
Recombinant DNA
pGEX6-His-EXD2 K76-V564 This study N/A
EXD2-peGFPN2 This study N/A
EXD2-pHAGE-N-Flag–HA Broderick et al., 2016 N/A
EXD2-pDEST-peGFP This Study N/A
pCMV-I-Sce1 a kind gift from Dr. V. Macaulay N/A
pmCherry-C1 Clontech N/A
Software and Algorithms
ImageJ NIH https://imagej.nih.gov
GraphPad Prism v7.00 GraphPad Prism version 7.00
GraphPad Software, La Jolla
California USA
https://graphpad.com
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LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to the Lead Contact, Wojciech Niedzwiedz
(wojciech.niedzwiedz@icr.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
HeLa and U2OS cells were a generous gift from Dr F. Esashi and were cultured in Dulbecco’s modified Eagle’s medium (DMEM) sup-
plemented with 10% fetal bovine serum (FBS) and standard antibiotics. HEK293FT cells and HeLa S3 cells were a generous gift from
Dr G. Stewart and Prof. I.D. Hickson, respectively, and were cultured in DEMEM supplemented with 10% FBS and standard antibi-
otics. U2OS cells stably expressing GFP-CtIP were a generous gift from Prof. S.P. Jackson and were cultured in media supple-
mented with 500 mg ml-1 G-418. U2OS EJ2-GFP cells were a kind gift of Prof. J. Stark. DLD1 WT and DLD1 BRCA2/ cell lines
were a kind gift fromProf. C. Lord andweremaintained in RPMImedia supplementedwith 10% fetal bovine serum, 2mML-Glutamine
and standard antibiotics. SUM149 and SUM149 revertant cell lines were a kind gift of Prof. C. Lord and were cultured in Ham’s F-12
medium supplemented with 10% fetal bovine serum, 5 mg/mL insulin, and 1 mg/mL hydrocortisone. U2OS cells stably expressing
FLAG-HA EXD2 (generated previously) were cultured in DMEM supplemented with 0.5 mg ml-1 Puromycin (GIBCO).
METHOD DETAILS
Cell Lines Generation
Cell lines stably expressing GFP EXD2 WT fusion proteins were generated by transfection of U2OS cells with this plasmid construct
followed by clonal selection of cells grown in media containing 500 mg ml-1 G418 (Life Technologies). HeLa EXD2/ cell lines stably
expressing FLAG-HA EXD2WT or D108A/E110A fusion proteins were generated by transfection of these cells with plasmid construct
followed by clonal selection of cells grown in media containing 0.25 mg ml-1 Puromycin (GIBCO).
U2OS and RPE1 EXD2/ cells were generated as previously described (Broderick et al., 2016). RPE1 EXD2ND/ND (D108A/E110A)
were generated using following gRNAs GTCTAATTCACTTCTAAGCAA and GACTTGGAATTGACTGTGAGT cloned into pAIO-NK
vector (a kind gift from Dr. A. Blackford) and ssODN AGGAGGCAGAGTGGGATCAAATCGAGCCCTTGCTTAGATCTGAATTAGAAGA
TTTTCCAGTACTTGGTATCGCTTGTGCGTGGGTAAGTTAAAAAGCAAAAGTTAAAAAA.
Plasmids and Cloning
Plasmid constructs employed to generate cell lines stably expressing FLAG EXD2 WT and FLAG EXD2 D108A/E110A were as pre-
viously described (Broderick et al., 2016). Plasmids expressing GFP-EXD2 were generated by cloning EXD2 into the pDEST-peGFP
(a generous gift from Prof C. Green) or the peGFPN2 plasmid (Clontech). Plasmids were transfected into human cells using Lipofect-
amine 2000 (Life Technologies), according to the manufacturer’s instructions. GST-His-EXD2 K76-V564 construct was obtained by
cloning His-EXD2 K76-564 (Broderick et al., 2016) into the pGEX-6P1 vector. The pCMV-I-Sce1 plasmid was a kind gift from
Dr V. Macaulay. pmCherry-C1 was obtained from Clontech.
Immunoblotting
Cell lysis was carried out in urea buffer (9M urea, 50mMTris HCL, pH 7.3, 150mM b-mercaptoethanol) followed by sonication using a
soniprep 150 (MSE) probe sonicator. In some instances, cells were lysed in SDS loading buffer (2% SDS, 10% (v/v) glycerol, 2%
2-Mercaptoethanol and 62.5 mM Tris-HCl, pH 6.8) followed by boiling for 10 min. Samples were resolved by SDS-PAGE and trans-
ferred to PVDF or nitrocellulose. Protein concentrations were determined by Bradford assay by spectrophotometry using a
NanoDrop 2000 device (Thermo Scientific). Immunoblots were carried out using the indicated antibodies: a-Tubulin (Sigma,
B-5-1-2; T5168, 1:100,000), BRCA1 (Millipore, OP-92, 1:1000), BRCA2 (Millipore, OP-95, 1:1000), EXD2 (Sigma, HPA005848,
1:1000), MCM2 (Abcam, ab4461, 1:10,000), MRE11 (Abcam, ab214, 1:1000), PCNA (Santa-Cruz, PC-10, 1:500), RECQ1 (Santa
Cruz, sc-166388,1:1000) and SMARCAL1 (Santa Cruz, sc-376377 1:1000).
Cell Survival and Proliferation Assays
Alamar Blue survival assays were performed in accordance with the manufacturer’s recommendations (Life Technologies). Briefly,
500 cells per well in 96-well plates were untreated or treatedwith indicated doses of camptothecin or ionising radiation and incubated
for 7 days. Alamar blue reagent (Life Technologies) was added to each well and fluorometric measurements taken after 2h incubation
at 37C. For proliferation assays cells were seeded at 500 cells per well and Alamar blue reagent added and measurements taken
each day as indicated.
RNAi treatment
siRNAs employed were as follows, siBRCA1- ACCAUACAGCUUCAUAAAUAA, siBRCA2 (ON-TARGETplus SMART pool L-003462-
00-0005, Dharmacon.), siEXD2 – CAGAGGACCAGGUAAUUUA, siMRE11 – GGAGGUACGUCGUUUCAGA, siRECQ1 (ON-
TARGETplus SMARTpool L-013597-00-0005) siSMARCAL1 (ON-TARGETplus SMARTpool L-013058-00-0005). ON-TARGETpluse3 Molecular Cell 75, 605–619.e1–e6, August 8, 2019
Non-targeting Pool (D-00180-10-20, Dharmacon), or siRNA targeting luciferase - CGTACGCGGAATACTTCGA were used as control
siRNAs where appropriate. Oligonucleotides were transfected using HiPerfect reagent (QIAGEN), according to the manufacturer’s
protocol.
IMMUNOFLUORESCENCE MICROSCOPY
For visualization of 53BP1 foci and OPT domains in Cyclin A-negative and -positive cells, respectively, cells were fixed with 4%para-
formaldehyde in PBS for 10 min at room temperature, washed twice in PBS and permeabilised with 0.2% Triton Triton X-100 in PBS
for 10min at room temperature. Coverslips werewashed 3 x in PBS and blocked in 10%FBS in PBS for 30min before incubation with
primary antibodies in 0.1%FBS in PBS for 1h at room temperature, washed 43 5min in PBS temperature followed by incubation with
secondary antibodies for 45min. Slides were thenwashed 43 5min in PBS andmountedwith Vectashield mountingmedium (Vector
Laboratories) with DAPI. Antibodies employed for immunofluorescence were as follows: 53BP1 (MAB3802, Millipore, 1:1000), Cyclin
A (sc751, Santa Cruz, 1:100).
For Phalloidin staining, cells were fixed and permeabilised as above and incubated with PBS containing Alexa Fluor 647- Phalloidin
(Thermo Fisher A22287, 1:50) before being mounted using Vectashield with DAPI.
For analysis of anaphase bridges cells were analyzed using a protocol adapted from Broderick et al. (2015). Briefly, cells were
collected by mitotic shakeoff and spun onto poly-L-Lysine coated slides at 1000 x g for 3 min. Mitotic cells were then fixed using
4% PFA in PBS for 10 min at room temperature and mounted with Vectashield containing DAPI. Images were acquired using a Zeiss
LSM 710 laser scanning confocal microscope with Zen software using a 63x objective. Image analysis was carried out with FIJI
(ImageJ) software.
EdU labeling of nascent DNA and Proximity Ligation Assay
The association of proteins to newly synthesized DNA using EdU labeling and the Proximity Ligation Assay was carried out as pre-
viously described (Taglialatela et al., 2017). Briefly, U2OS cells or U2OS cells stably expressing GFP or FLAG-HA EXD2 were grown
on coverslips before being labeled with 10 mMEdU for 10min followed in some cases by treatment with 4mMhydroxyurea for various
amounts of time as indicated.
Cells were then permeabilized using 0.5%Triton in PBS for 10min at 4C,washed twice in PBS and fixed at with 3% formaldehyde,
2% sucrose in PBS for 10min at room temperature. Post-fixation, cells were washed twice PBS and incubated with blocking solution
(3%BSA in PBS) for 30 min. Slides were washed twice with PBS before conjugation of Biotin Azide to the newly incorporated EdU by
click chemistry using theClick-iT reaction. TheClick-iT reactionwas carried using aCick-iT assay kit (Thermo Fisher) according to the
manufacturer’s instructions using 20 mM biotin-azide for 30 min. Coverslips were washed twice with PBS before incubation with the
indicated primary antibodies for 1h at room temperature in 1% BSA/0.1% saponin in PBS.
Following primary antibody incubation coverslips were washed twice in PBS and then the proximity ligation assay was carried out
using the Duolink In SituRed Starter kit (Sigma Aldrich) according to the manufacturer’s instructions. Coverslips weremounted using
Vectashield containing DAPI. For the PLA assay between GFP-EXD2 and BRCA1, cells were treated with HU for the indicated time
before fixation in methanol at 20C for 20 min followed by 3 washes with PBS. Blocking, primary antibody incubation and the PLA
assay were then carried out as described above. Antibodies employed for the PLA assay were as follows: Biotin (Bethyl Laboratories,
A150-109A, 1:3000), Biotin (Jackson Immunoresearch, 200-002-211, 1:1000), BRCA1 (Santa Cruz, sc6954, 1:500), FLAG (Sigma,
M2, 1:500), (GFP (Abcam, ab290, 1:500), GFP (Roche, 11 814 460 001, 1:500), MRE11 (Abcam, ab214, 1:100), PARP1 (Santa
Cruz, sc-5364, 1:500), Rad51 (Calbiochem, PC130, 1:500). Images were acquired using a Zeiss LSM 710 laser scanning confocal
microscope with Zen software using a 63x objective. Image analysis was carried out with FIJI (ImageJ) software.
iPOND
Logarithmically growing HeLa S3 cells (13 106 per ml) or HEK293FT cells were incubated with 10 mM EdU for 10 minutes. Following
EdU labeling, cells were fixed in 1% formaldehyde, quenched by adding glycine to a final concentration of 0.125M andwashed three
times in PBS. Collected cell pellets were frozen at80C and cells were permeabilized by resuspending 1.0–1.53 107 cells per ml in
ice cold 0.25% Triton X-100 in PBS and incubating for 30 minutes. Before the Click reaction, samples were washed once in PBS
containing 0.5% BSA and once in PBS. Cells were incubated for 1 hour at room temperature in Click reaction buffer containing
10 mM azide-PEG(3+3)-S-S-biotin conjugate (Click ChemistryTools, cat. no AZ112-25), 10 mM sodium ascorbate, and 1.5 mM cop-
per (II) sulfate (CuSO4) in PBS. The ‘no Click’ reaction contained DMSO instead of biotin-azide. Following the Click reaction, cells
were washed once in PBS containing 0.5% BSA and once in PBS. Cells were resuspended in lysis buffer (50 mM Tris–HCl pH
8.0, 1% SDS) containing protease inhibitor cocktail (Sigma) and sonicated with a Diagenode Bioruptor Plus for 40 cycles (30 s
on/30 s off). Samples were centrifuged at 14,500 rcf. at 4C for 30 minutes and the supernatant was diluted 1:3 with TNT buffer
(50 mM Tris pH 7.5, 200 mM NaCl and 0.3% Triton X-100) containing protease inhibitors. An aliquot was taken as an input sample.
Streptavidin–agarose beads (Novagen) were washed three times in TNT buffer containing protease inhibitor cocktail. Two hundred
microliters of bead slurry was used per 1x 108 cells. The streptavidin–agarose beads were resuspended 1:1 in TNT buffer containing
protease inhibitors and added to the samples, whichwere then incubated at 4C for 16 hours in the dark. Following binding, the beads
were then washed two times with 1 mL TNT buffer, two times with TNT buffer containing 1M NaCl, two times with TNT buffer andMolecular Cell 75, 605–619.e1–e6, August 8, 2019 e4
protein–DNA complexes were eluted by incubating with 5mMDTT in TNT buffer. Cross-links were reversed by incubating samples in
SDS sample buffer at 95C for 20 minutes. Proteins were resolved on SDS-PAGE and detected by immunoblotting using specific
antibodies.
DNA fiber analysis
DNA fiber assay was performed as described previously with some modifications (Schwab et al., 2015). In brief, exponentially
growing cells were first incubated with 25 mM iododeoxyuridine (IdU) and then with 125 mM chlorodeoxyuridine (CldU) for the indi-
cated times. Fiber spreads were prepared from 0.5 x106 cells/ml. Slides were stained as described previously . A confocal micro-
scope (LSM 510 Meta or LSM 710 Meta; Carl Zeiss) equipped with Plan-Apochromat 633 /1.4 oil DIC objective was used to collect
fiber images from randomly selected fields at RT using ZEN 2009 software (Carl Zeiss). Analysis was performed using the ImageJ
software package (National Institutes of Health). A minimum of 100 fibers or 20 sister fork pairs per experiment from at least three
independent experiments was scored. Mann-Whitney test was used to determine statistical significance. On boxplots whiskers indi-
cate 5-95 percentile.
Protein Purification
GST-His- EXD2 K76-V564 was purified as described previously with some modifications. Briefly, GST protein expression was
induced with 0.1 mM IPTG (isopropyl-b-d-thiogalactopyranoside) (Sigma-Aldrich) at 16C for 18 hours. Bacteria were harvested
by centrifugation and resuspended in lysis buffer containing 50 mM phosphate pH 8.0, 300mM NaCl, 1 mM DTT, 1% Triton
X-100, 10mM imidazol and PMSF. Lysates were sonicated and cleared by centrifugation. Supernatants were incubated with Ni resin
(QIAGEN) for 2 h with rotation at 4C. Beads were washed with lysis buffer containing 20 mM imidazol, and eluted with lysis buffer
containing 300 mM imidazole. Eluates were then incubated with Glutathione HiCap Matrix (QIAGEN) for 2 h with rotation at 4C.
Beads were washed with buffer containing increasing concentration of NaCl, elution buffer (50 mM Tris-HCl pH 7.0, 150 mM
NaCl, 1 mM EDTA, 1 mM DTT, 0.2% Triton X-100) and resuspended in elution buffer supplemented with PreScission Protease
(50 units/ml) (GE Healthcare) and incubated for 18 h with rotation at 4C. Eluates were dialysed to buffer containing 20 mM
HEPES-KOH pH7.2, 100 mM NaCl, 1 mM DTT, 10% glycerol, aliquoted and stored at 80C.
In vitro nuclease assay
Sequences of DNA oligos used are listed in Table S1. To generate 50 end labeled substrates, the indicated ssDNA oligo was labeled
using [g-32P] dATP and PNK enzyme (New England Biolabs). To obtain fork substrates, ssDNA oligos (as indicated in Table S1) were
mixed in an equimolar ratio and annealed by heating at 100C for 5 min followed by gradual cooling to room temperature.
Exonuclease assays were performed as described. Briefly, reactions were carried out in a buffer containing 20 mM HEPES-
KOH, pH 7.5, 50mMKCl, 0.5mMDTT, 10mMMnCl2, 0.05%Triton-X, 0.1mgml
-1 BSA, 5%glycerol, and EXD2 protein (25 nMunless
stated otherwise) and initiated by adding substrate (3nM unless stated otherwise) and incubated at 37C for the indicated amounts of
time. Reactions were stopped by addition of EDTA to a final concentration of 20mMand 1/5 volume of formamide. The samples were
resolved on denaturing 15% or 20% polyacrylamide TBE-Urea gels. Gels were fixed, dried and visualized using a Typhoon FLA 9500
instrument (GE Healthcare).
Recruitment of GFP-tagged proteins to laser localized DNA damage
Cells were grown on glass bottomed culture dishes (MatTekTM, 35mm). Plates were placed in an environmental chamber maintained
at 37C, 5%CO2, 80%humidity, mounted on the stage of a Nikon TE2000 spinning diskmicroscope. Cells were visualizedwith a Plan
Fluor3 60/1.25 numerical aperture oil objective. Themicroscope was equipped with an SRSNL100 nitrogen laser-pumped dye laser
(Photonics Instruments, St. Charles, IL). To introduce DNA damage a defined region of interest (ROI, 43 20 pixels, 0.16 mm/pixel) in
an individual nucleus was exposed to the laser firing 3-ns pulses at 365 nmwith a repetition rate of 10 Hz. The laser was controlled by
Volocity-5 software (Improvision; PerkinElmer Life Sciences). The beam was oriented by galvanometer-driven displacers and fired
randomly throughout the region until the entire region was exposed. Images were taken before targeting and at defined intervals after
targeting to detect the GFP-tagged protein recruitment to the targeted stripe. Volocity Software was used to quantify the intensity of
the GFP signal at the damage site and at an equivalent area in a non-targeted region of the nucleus (background). Graphs show
[GFP Intensity at the stripe/ GFP intensity at non-targeted stripe in the same nucleus] as a function of time in arbitrary units. The
average of at least 10 cells was graphed for each experiment. Error bars represent the standard deviation.
Chromosomal aberrations analysis
Sub-confluent cultures of HeLa WT and the of HeLa EXD2/ cl.1 and cl.2 cells, grown in DMEM with 10% FBS (GIBCO-BRL) plus
antibiotics, at 37C, were exposed to DMF (Sigma), 20 mM Cisplatin (Sigma) diluted in DMF for 16 h or 4 Gy X-ray irradiation. Two
hours before harvest, the cells were exposed to colcemid (0.1mg/ml) (GIBCO). Cells were harvested by trypsinization (GIBCO), re-
suspended in culture medium and then spun down (10 minutes at 1000 rpm). Supernatant was removed, and then 0.075 M KCl
(Sigma) at room temperature was added drop by drop. For hypotonic treatment, cell suspensions were incubated for
20minutes at room temperature, and then 1mL of fixative 3:1methanol (ApplichemGmbH, Darmstadt, Germany)-acetic acid (Merck,
Darmstadt, Germany) was added. Cells were re-centrifuged for 10 minutes at 1000 rpm, supernatant was removed, fixative wase5 Molecular Cell 75, 605–619.e1–e6, August 8, 2019
added, and then re-centrifuged in fixative for another two times. Finally, chromosome preparations were dropped onto wet
microscope slides and left to air-dry. For inverted DAPI chromosome banding staining, slides were mounted with 0.1mg/ml DAPI
in Vectashield antifade medium (Vector Laboratories, Burlingame, CA). Images of chromosome spreads were captured using a
x63 magnification lens on a fluorescent Axio-Imager Z1, Zeiss microscope, equipped with a MetaSystems charge-coupled device
camera and the MetaSystems Isis software. Chromosome lesions were recorded as breaks per chromosome number, per
metaphase, in 75 metaphase spreads per condition, pooled from 3 independent experiments.
Alt-EJ GFP reporter assay
48 hours after siRNA transfection, U2OS EJ2-GFP cells (Gunn et al., 2011) were transfected using Amaxa nucleofection with an I-SceI
expression vector (pCMV-I-SceI) or a vector expressing mCherry fluorescent protein (pmCherry-C1). 72 hours after I-SceI transfec-
tion cells were harvested and analyzed by flow cytometry (BD LSR II). 2x104 cells were analyzed per experimental condition. Number
of GFP-positive cells per 1000 mCherry-positive cells was determined using BD FACS DIVA software. The data were then related in
each experiment to siControl treated sample set as 1. Statistical significance was determined with the Student’s t test.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical calculations were done using GraphPad Prism 7 (GraphPad Software Inc.). Unpaired Student’s t test, Chi square test or
Mann Whitney test were used to determine statistical significance as indicated in the Figure Legends. Sample sizes are indicated in
the Figure Legends.Molecular Cell 75, 605–619.e1–e6, August 8, 2019 e6
